Compare · ETHZ vs NVO
ETHZ vs NVO
Side-by-side comparison of ETHZilla Corporation (ETHZ) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ETHZ and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $183.15B.
- Over the past year, ETHZ is down 95.2% and NVO is down 45.7% - NVO leads by 49.5 points.
- NVO has hit the wire 8 times in the past 4 weeks while ETHZ has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for ETHZ).
- Company
- ETHZilla Corporation
- Novo Nordisk A/S
- Price
- $3.53-7.83%
- $41.01-4.51%
- Market cap
- -
- $183.15B
- 1M return
- -26.92%
- -10.44%
- 1Y return
- -95.20%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ETHZ
- Forum to Present at Sidoti's Small-Cap Virtual Investor Conference on March 18
- Forum Announces Fourth Quarter and Year-End 2025 Earnings Release Date and Webcast Details
- Forum Appoints Robert Spake as General Counsel
- ETHZilla Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- ETHZilla Becomes Forum in Next Step of Strategic Evolution Toward Institutional-Grade Real-World Asset Tokenization
- Director Smith Ryan Lewis disposed of 16,718 shares (SEC Form 4)
- ETHZilla Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- ETHZilla Announces First Ever Tradable Tokenized Aviation Assets on Ethereum Network Secured by Jet Engines on Lease with a Leading U.S. Air Carrier
- Amendment: SEC Form SCHEDULE 13G/A filed by ETHZilla Corporation
- ETHZilla Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Regulation FD Disclosure
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care